| Literature DB >> 34937820 |
Philip Dueppers1, Lorenz Meuli1, Benedikt Reutersberg1, Michael Hofmann1, Florian Messmer2, Alexander Zimmermann1.
Abstract
PURPOSE: To compare open versus endovascular left subclavian artery debranching for thoracic endovascular aortic repair of thoracic aortic pathologies.Entities:
Keywords: TEVAR; aortic dissection; endoleak; parallel grafts; thoracic aortic aneurysm
Mesh:
Year: 2021 PMID: 34937820 PMCID: PMC9209886 DOI: 10.5761/atcs.oa.21-00206
Source DB: PubMed Journal: Ann Thorac Cardiovasc Surg ISSN: 1341-1098 Impact factor: 1.889
Demographic and disease-specific data
| Characteristics | ENDO (n = 24) | OPEN (n = 24) | p value |
|---|---|---|---|
| Female | 8 (33%) | 9 (38%) | 0.763 |
| Median age, years (IQR) | 75 (70-80) | 71 (59-75) | 0.103 |
| ASA Class 2 | 1 (4%) | 0 (0%) | 0.312 |
| Arterial hypertension | 19 (79%) | 17 (71%) | 0.505 |
| Tobacco use | 10 (42%) | 6 (25%) | 0.221 |
| Lipid disorder | 9 (37%) | 5 (21%) | 0.204 |
| Chronic kidney injury | 8 (33%) | 4 (17%) | 0.182 |
| Coronary artery disease | 4 (17%) | 2 (8%) | 0.383 |
| Stroke | 4 (17%) | 2 (8%) | 0.383 |
| Cancer | 3 (13%) | 2 (8%) | 0.637 |
| Chronic obstructive pulmonary disease | 2 (8%) | 2 (8%) | 1.00 |
| Prior myocardial infarction | 1 (4%) | 2 (8%) | 0.551 |
| Diabetes mellitus type II | 0 (0%) | 3 (13%) | 0.074 |
| Peripheral arterial occlusive disease | 1 (4%) | 2 (8%) | 0.551 |
| Cerebral vascular disease | 0 (0%) | 1 (4%) | 0.312 |
| Congestive heart failure | 0 (0%) | 1 (4%) | 0.312 |
| Preoperative antithrombotic medication None APT OAC + APT OAC DAPT | 9 (37%) | 9 (37%) | 0.113 |
| Earlier thoracic aortic procedures Ascending aorta repair Alone + Hemiarch repair + TEVAR TEVAR Patchplasty for aortic isthmus stenosis Thoraco-abdominal aortic replacement | 8 (33%) | 11 (46%) | 0.546 |
| Type B aortic dissection Acute Chronic | 13 (54%) | 12 (50%) | 0.773 |
| Degenerative aortic aneurysm Thoracic aorta Thoraco-abdominal aorta | 6 (25%) | 6 (25%) | 1.00 |
| Type IA endoleak | 3 (13%) | 3 (13%) | 1.00 |
| Patchplasty-associated aneurysm | 2 (8%) | 0 (0%) | 0.149 |
| Penetrating aortic ulcer | 0 (0%) | 1 (4%) | 0.312 |
| Para-anastomotic aneurysm | 0 (0%) | 1 (4%) | 0.312 |
| Left subclavian artery branch aneurysm | 0 (0%) | 1 (4%) | 0.312 |
| Mean maximum aortic diameter | 56 ± 14 | 58 ± 14 | 0.687 |
* Statistical significance
ASA: American Society of Anesthesiologists; (D)APT: (dual) antiplatelet therapy; IQR: interquartile range; OAC: oral anticoagulants; TEVAR: thoracic endovascular aneurysm repair
Operative data
| Characteristics | ENDO (n = 24) | OPEN (n = 24) | |
|---|---|---|---|
| Procedures Single staged Two staged | 24 (100%) | 11 (46%) | <0.001* |
| Emergency procedures | 7 (29%) | 1 (4%) | 0.020* |
| Median operation time, cumulated, min (IQR) Only single-staged procedures | 117 (105–149) | 207 (170–284) | <0.001* |
| Median length of in-hospital stay, cumulated, days (IQR) Only single-staged procedures | 6 (5–10) | 15 (10–20) | <0.001* |
| Median intensive/intermediate care, cumulated, days (IQR) Only single-staged procedures | 0 (0–1) | 2 (1–9) | 0.002* |
| Debranching technique Sandwich Periscope Chimney Carotid-axillary bypass Carotid-LSA bypass LSA-to-carotid transposition | 10 (42%) | – | n.a. |
| Planned additional/adjunctive procedures EVAR EIA stent grafting for distal entry occlusion Iliac-femoral conduit | 3 (13%) | 1 (4%) | 0.394 |
| Intraoperative complications | 3 (13%) | 1 (4%) | 0.296 |
| Postoperative antithrombotic medication OAC + APT APT OAC DAPT | 24 (100%) | 24 (100%) | 1.00 |
* Statistical significance
(D)APT: (dual) antiplatelet therapy; IQR: interquartile range; LSA: left subclavian artery; n.a.: not applicable; OAC: oral anticoagulants; EVAR: endovascular aortic repair; EIA: external iliac artery
Early and late results of open versus endovascular debranching
| Characteristics | ENDO (n = 24) | OPEN (n = 24) | p value |
|---|---|---|---|
|
| |||
| Median follow-up for first CTA, days (IQR) | 2 (1–4) | 1 (1–2) | 0.121 |
| Type I endoleaks Type IA Type IB Type IC | 19 (79%) | 3 (13%) | <0.001* |
| Procedure-related reinterventions | 6 (25%) | 3 (13%) | 0.267 |
| LSA debranching failure | 2 (8%) | 0 (0%) | 0.149 |
| Stroke | 0 (0%) | 2 (8%) | 0.149 |
| 30-days mortality, all-cause | 2 (8%) | 3 (13%) | 0.637 |
| 30-days mortality, aorta-related | 1 (4%) | 1 (4%) | 1.00 |
|
| |||
| Patients available | 22 (92%) | 21 (87%) | 0.637 |
| Median follow-up for first CTA >30 days, months (IQR) | 3 (2–4) | 2 (2–3) | 0.438 |
| Technical success | 8 (36%) | 17 (81%) | 0.003* |
|
Type I endoleak Type IA Type IB Type IC | 13 (59%) | 2 (10%) | 0.001* |
|
Type III endoleaks | 0 (0%) | 2 (10%) | 0.138 |
| Clinical success | 8 (36%) | 14 (67%) | 0.047* |
|
LSA debranching failure | 2 (8%) | 0 (0%) | 0.157 |
|
| |||
| Patients available | 21 (88%) | 20 (83%) | 0.683 |
| Median follow-up for last CTA, months (IQR) | 52 (33–71) | 21 (14–59) | 0.062 |
| Persisting type I endoleaks Type IA Type IB Type IC | 9 (43%) | 0 (0%) | 0.001* |
| Median follow-up for survival, months (IQR) | 52 (22–68) | 16 (8–48) | 0.061 |
| Median follow-up for CTA, months (IQR) | 48 (22–68) | 16 (8–48) | 0.093 |
| Median follow-up for aortic reintervention, months (IQR) | 26 (4–57) | 15 (3–31) | 0.458 |
| Overall aortic reinterventions Type I endoleak Type II endoleak Type III endoleak Retrograde type A aortic dissection | 8 (33%) | 6 (25%) | 0.525 |
| Overall LSA debranching failure | 3 (13%) | 1 (5%) | 0.317 |
| Overall mortality, all-cause | 9 (38%) | 6 (25%) | 0.393 |
| Overall mortality, aorta-related | 4 (17%) | 3 (13%) | 1.00 |
Percentages are based on the number of patients available for follow-up. Overall rates and corresponding percentages are calculated based on the initial patient number
*Statistical significance
CTA: computed tomography angiography; IQR: interquartile range; LSA: left subclavian artery; n.a.: not applicable
Fig. 1Kaplan–Meier analysis of freedom from overall aortic reintervention (A), overall all-cause mortality (B), and aorta-related mortality (C).
Published results of open and parallel graft-based left subclavian artery debranching during zone 2 TEVAR
| Group | Technique | Author | Design | Year | Patients | Median FU | 30-day mortality | Stroke | Primary EL I | Technical success | Overall aortic reintervention | Overall mortality, all-cause | Primary EL I | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All-cause | Aorta related | |||||||||||||
| OPEN | CSB + SCT | Luehr et al. | Single cohort | 2019 | 55 | 16.8 | 4 (7.3) | n.d. | 3 (5.5) | 7 (12.8) | n.d. | 7 (12.8) | 7 (12.7) | n.d. |
| OPEN | CSB + SCT | D’Oria et al. | Single cohortc | 2020 | 721 | 1 | 24 (3.3) | 16 (2.2) | 36 (5.0) | 19 (2.6) | n.d. | n.d. | n.d. | n.d. |
| OPEN | CSB | Xiang et al.17) | Comparative | 2018 | 14 | –(39.9a) | 1 (7.1) | 0 (0) | 0 (0) | 1 (7.1) | 13 (92.9) | 1 (7.7) | 1 (7.1) | 0 (0) |
| OPEN | CSB | Piffaretti et al. | Comparative | 2018 | 42 | 15 | n.d. | 1 (2.4) | 1 (2.4) | n.d. | 41 (97.6) | 2 (4.8) | n.d. | n.d. |
| OPEN | CSB + SCT | Johnson et al.15 | Comparative | 2021 | 35 | 26.2 | 0 (0) | 0 (0) | 1 (2.9) | 0 (0) | n.d. | 9 (25.7) | 1 (2.9) | 0 (0) |
| OPEN | CSB | Ramdon et al.16) | Comparative | 2020 | 64 | 14.5 | 2 (3.1) | n.d. | 4 (6.3) | 3 (4.6) | n.d. | n.d. | n.d. | n.d. |
| OPEN | CSB + CAB + SCT | Own study | Comparative | 2021 | 24 | 16 | 3 (13) | 1 (4) | 2 (8) | 3 (13) | 17 (81) | 6 (25) | 6 (25) | 0 (0) |
| ENDO | Chimney | Xue et al.9) | Single cohort | 2015 | 59 | 16.5 | 0 (0) | 0 (0) | 2 (3.4) | 5 (8.5) | 58 (98.3) | n.d. | 3 (5.1) | 5 (8.5) |
| ENDO | Chimney | Ding et al.18 | Single cohort | 2019 | 159 | –(23a) | 3 (1.9) | 1 (0.6) | 3 (1.9) | 36 (22.6) | 129 (81) | 1 (0.6) | 6 (3.8) | 4 (3.3) |
| ENDO | Chimney | Piffaretti et al. | Comparative | 2018 | 31 | 15 | n.d. | 2 (6.4) | 1 (3.2) | n.d. | 31 (100) | 2 (6.5) | n.d. | 4 (13) |
| ENDO | Chimney | Xiang et al.17) | Comparative | 2018 | 24 | –(21.3a) | 0 (0) | 0 (0) | 0 (0) | 10 (41.7) | 24 (100) | 3 (12.5) | 0 (0) | 5 (20.8) |
| ENDO | Chimney | Ramdon et al.16) | Comparative | 2020 | 17 | 8 | 0 (0) | n.d. | 1 (5.9) | 0 (0) | n.d. | n.d. | n.d. | n.d. |
| ENDO | Periscope | Johnson et al.15) | Comparative | 2021 | 18 | 11 | 0 (0) | 0 (0) | 0 (0) | 7 (39) | n.d. | 6 (33.3) | 3 (16.7)b | 2 (11.1) |
| ENDO | Both | Own study | Comparative | 2021 | 24 | 36 | 2 (8) | 1 (4) | 0 (0) | 19 (79) | 8 (36) | 8 (33) | 9 (38) | 9 (43) |
Results are given as numbers (percentage) or months for follow-up
a Mean; b Aorta-specific; c Endovascular group was not used for comparison, because only 20% received parallel grafts and subgroup analysis was not performed
CAB: carotid-axillary bypass; CSB: carotid-subclavian bypass; EL I: type I endoleak; FU: median follow-up; n.d.: not described; SCT: subclavian-carotid transposition; TEVAR: thoracic endovascular aneurysm repair